News
Jaime Almandoz, MD, MBA, of UT Southwestern Medical Center, speaks on results of a study that investigated tirzepatide uptake ...
Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...
Adults with overweight or obesity plus prediabetes maintain most of their weight loss with tirzepatide at more than 3 years, ...
For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...
This post hoc analysis of the SURMOUNT-1 study, at three years, aimed to assess weight regain from nadir weight over three years (36 months / 176 weeks) with tirzepatide treatment. Weight regain ...
HealthDay News — After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering medications (GLMs) and among adults without diabetes ...
Tirzepatide's uptake was rapid post-launch, surpassing other GLP-1 RAs and SGLT2 inhibitors, while conventional GLMs like metformin and insulin declined. The approval of tirzepatide for type 2 ...
News Medical on MSN10d
3-year study of tirzepatide shows that most patients only gain 5% or less from their lowest or ‘nadir’ weightNote – this is an early press release from the European Congress on Obesity in Malaga, Spain, 11-14 May. Please credit the congress when using this research.* New research to be presented at this year ...
“Our long-term analysis of tirzepatide establishes that clinically relevant weight loss can be sustained for up to three years,” Dr. Busetto noted. He added, “Regardless of age, BMI, and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback